The Oregon Cancer Center was created in 1991 as a multidepartmental institute of Oregon Health Sciences University in Portland. The goals of the center are to support both basic and clinical cancer research activities on this campus and to facilitate application of the latest research opportunities to the diagnosis, treatment, and prevention of malignant diseases. The Center received support through a Cancer Center Planning Grant (P20) in 1992. The Center has four scientific programs (Caner Biology, Hormonal and Reproductive Cancers, Hematologic Malignancies, and Experimental Therapeutics) and one developing program (Cancer Prevention and Control) with effect our shared views that: (a) the best new strategies for diagnosis, treatment, and control depend upon the identification of specific pathophysiological significant molecular defects in neoplastic cells and (b) a comprehensive definition of normal cellular growth and differentiation is required to define specific molecular defects in neoplastic cells. In support of the activities of the center are seven shared resources (Flow Cytometry, Molecular Biology, Tumor Procurement, Cell Culture and Expression, Animal Models, Biostatistics, and Clinical Research Management). The commitment of more than $27 million to our development has resulted, to date, in the recruitment of 29 new members to the facilities of various Departments in the University, creation of seven shared facilities, and design, construction, or renovation of new space. The Cancer Center Director controls 21,825 square feet of centrally located space of campus (11,000 square feet of which represents the top floor of a new building that will serve as our Headquarters in July 1997, the move-in date). In November 1998 our space will more than double by virtue of the completion of a $32.2 million Cancer Research building on the VA campus, half of which will be assigned to the Center. The Center has established a new set of operating principles that have resulted in the creation of a variety of innovative institutional clinical trials on this campus. Consequently, the Oregon Cancer Center has gained widespread acceptance by both basic and clinical cancer research faculty on this campus and has been welcomed by cancer caregivers throughout Oregon and Southwestern Washington.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA069533-03S1
Application #
2858502
Study Section
Special Emphasis Panel (ZCA1-SRRB-3 (J1))
Program Officer
Ciolino, Henry P
Project Start
1997-08-01
Project End
2000-05-31
Budget Start
1999-07-12
Budget End
2000-05-31
Support Year
3
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009584210
City
Portland
State
OR
Country
United States
Zip Code
97239
Su, Yulong; Pelz, Carl; Huang, Tao et al. (2018) Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals. Genes Dev 32:1398-1419
Gast, Charles E; Silk, Alain D; Zarour, Luai et al. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv 4:eaat7828
Krey, Jocelyn F; Scheffer, Deborah I; Choi, Dongseok et al. (2018) Mass spectrometry quantitation of proteins from small pools of developing auditory and vestibular cells. Sci Data 5:180128
Rozanov, Dmitri V; Rozanov, Nikita D; Chiotti, Kami E et al. (2018) MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection. J Proteomics 176:13-23
Winters-Stone, Kerri M; Wood, Lisa J; Stoyles, Sydnee et al. (2018) The Effects of Resistance Exercise on Biomarkers of Breast Cancer Prognosis: A Pooled Analysis of Three Randomized Trials. Cancer Epidemiol Biomarkers Prev 27:146-153
Pennock, Nathan D; Martinson, Holly A; Guo, Qiuchen et al. (2018) Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer. J Immunother Cancer 6:98
Xu, Li; Gordon, Ryan; Farmer, Rebecca et al. (2018) Precision therapeutic targeting of human cancer cell motility. Nat Commun 9:2454
Chen, Emerson Y; Blanke, Charles D; Haller, Daniel G et al. (2018) A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer. Am J Clin Oncol 41:1193-1198
Lane, Ryan S; Femel, Julia; Breazeale, Alec P et al. (2018) IFN?-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin. J Exp Med 215:3057-3074
Smith, Nicholas R; Swain, John R; Davies, Paige S et al. (2018) Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations. Cell Mol Gastroenterol Hepatol 6:79-96

Showing the most recent 10 out of 277 publications